[Focus Stock] PharmaResearch Plunges 17% on Weak Q4 Earnings View original image

PharmaResearch's share price is plunging after the company reported fourth-quarter results last year that fell short of market expectations.


As of 9:45 a.m. on February 5, PharmaResearch was trading at 361,000 won, down 17.86% from the previous trading day.


PharmaResearch announced in a filing the previous day that it posted sales of 142.8 billion won and operating profit of 51.8 billion won in the fourth quarter of last year. These figures are 7.7% and 20.4% below the market consensus, respectively.


Shin Minsoo, an analyst at Kiwoom Securities, said in a report released the same day, "The medical device Rejuran underperformed expectations in both domestic and export markets," adding, "Its absence was partially offset by the cosmetics lineup, but that was not enough to meet the consensus."


Regarding why the results also significantly undershot Kiwoom Securities' own earnings estimates, which had been set more conservatively than market expectations, Analyst Shin explained, "The reasons include a structural weakness in revenue, a 5 billion won reduction due to a change in revenue recognition accounting standards, increased R&D expenses related to anticancer drug development and clinical trials for Rejuran in Japan, and higher advertising and promotion expenses such as TV commercials for the Rejuvenex cream ointment."



Analyst Shin stressed, "The Google Trends index, foreign ownership ratio, and valuation indicators have all clearly entered a downward trend," and added, "For the share price to rebound, Rejuran's sales and traffic need to recover."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing